tRNA Therapeutic Technology Landscape — PatSnap Eureka
tRNA Therapeutic Technology Landscape 2026
From ACE-tRNAs suppressing nonsense mutations to plant-derived tRF anticancer agents, tRNA biology is emerging as a multi-platform therapeutic frontier. Explore 85+ patent and literature signals mapped by PatSnap Eureka.
Four Mechanistic Clusters Defining tRNA Therapeutics
tRNA therapeutic technology spans four distinct mechanistic platforms, each with a unique technical basis, translational trajectory, and competitive landscape. Understanding these clusters is essential for IP analytics and R&D prioritisation.
Anticodon-Engineered tRNAs (ACE-tRNAs)
Synthetic tRNAs with modified anticodons engineered to decode premature termination codons (PTCs), enabling restoration of full-length protein from disease-causing nonsense mutations. A novel vaccine application uses PTC-containing attenuated viruses controlled by exogenous ACE-tRNA switches. Harbin Veterinary Research Institute (2022) demonstrated ACE-tRNAs outperform conventional GCE technology in PTC readthrough potency using an HIV-1 pseudotyped virus model.
Nonsense suppression · Vaccine platforms · Rare diseasetRNA-Derived Small RNAs (tRFs & tiRNAs)
Fragments cleaved from mature or precursor tRNAs that act as microRNA-like post-transcriptional regulators, translational suppressors, or oncogene silencers via AGO2-mediated pathways. tRF-T11, derived from Chinese yew tRNAHis(GUG), demonstrated comparable anticancer potency to taxol at 16-fold lower dosage against ovarian cancer cells via TRPA1 targeting, as reported by Increasepharm (HK) Limited (2022).
Oncology · Cross-kingdom RNA · AGO2/RISCAminoacyl-tRNA Synthetase (aaRS) Inhibition
Pathogen-specific aaRS enzymes — particularly in Plasmodium falciparum, trypanosomes, and fungi — diverge structurally from human orthologs, enabling selective inhibition. The University of Dundee (2022) published a comprehensive drug discovery toolkit for PfKRS including crystal structures, resistance mutants, and chemical probes. Tryptophanyl-tRNA synthetase (WRS) is also proposed as a multi-indication target across sepsis, cancer, and autoimmune diseases.
Antimalarial · Anti-trypanosomal · OncologytRNA Modifications as Therapeutic Targets
Post-transcriptional modifications including pseudouridine (Ψ), methylation (m1A, m5C), and thiolation regulate tRNA structure, stability, aminoacylation efficiency, and innate immune interactions. The University of Chicago (2023) showed that T-arm modifications (m5U54 and Ψ55) by TrmA and TruB globally regulate aminoacylation and selective translational output — revealing systemic fitness consequences of modification loss. Penn State (2013) demonstrated tRNA modifications suppress PKR activation.
TRUB1/2 · PUS10 · TrmA · TruB · ELAC1/2From Foundational Biology to Therapeutic Acceleration
Across 85+ retrieved records, publication and filing dates span 1979 to 2025, revealing a field with deep foundational roots but a sharp acceleration of therapeutic application from 2019 onward. The earliest patent in this dataset is from Boehringer Ingelheim (1979, DE) — an antiviral tRNA preparation now inactive — indicating that the antiviral potential of tRNA preparations was recognized at least four decades ago.
The early development cluster (2006–2016) focused predominantly on tRNA biology infrastructure: sequencing methods (DM-tRNA-seq, 2015), nuclear export dynamics, tRF discovery and cataloguing (MINTbase v1, 2016), and tRNA modifications in immune evasion. HIV-1 tRNA interactions received attention as indirect therapeutic angles, including tRNALys3 as a reverse transcription primer studied by the University of Cincinnati (2016).
Mid-stage development (2017–2021) saw significant expansion of tRF databases, including MINTbase v2.0 from Thomas Jefferson University (2017) and DBtRend from Catholic University of Korea (2021), laying the bioinformatics scaffolding for clinical translation. According to NIH-funded research, ELAC enzymes were characterised as tRF generators in viral infection models. The tryptophanyl-tRNA synthetase was proposed as a therapeutic target by KRIBB/Korea University of Science and Technology (2021).
The most recent signals (2022–2025) include ACE-tRNA vaccine platforms, plant-derived tRF anticancer agents, a complete PfKRS drug discovery toolkit from the University of Dundee, and an active EP patent from Arcturus Therapeutics on high-potency synthetic mRNA constructs. Patent activity from TRON and BioNTech SE reflects growing commercialisation pressure in RNA oncology, tracked via PatSnap analytics.
tRNA Therapeutic Data Signals Visualised
Patent filing distribution and application domain activity derived from PatSnap Eureka's analysis of 85+ records in the tRNA therapeutic dataset.
Patent Filing Jurisdiction Distribution
Among ~15 distinct patent records, Israel leads with 5 filings, followed by EPO with 3, reflecting European biotech concentration in RNA therapeutics.
Application Domain Activity by Record Count
Oncology dominates tRNA therapeutic applications across both patents and literature, followed by infectious diseases spanning HIV, malaria, RSV, and trypanosomiasis.
Patent Assignees and Filing Status by Domain
Top patent assignees mapped across application domains, with filing status and jurisdiction from the PatSnap Eureka dataset.
Access full assignee intelligence and freedom-to-operate analysis
PatSnap Eureka surfaces patent landscapes, claim maps, and competitive white space across all tRNA therapeutic sub-domains.
Five Strategic Signals Shaping tRNA Therapeutics
Based on the most recent records in the PatSnap Eureka dataset, these directional signals represent the leading edges of tRNA therapeutic innovation.
ACE-tRNA as Programmable Vaccine Platform
The application of ACE-tRNAs beyond rare disease nonsense suppression into vaccine virology — using PTC-containing attenuated viruses controlled by exogenous ACE-tRNA switches — is an emerging paradigm. The Harbin VRI study (2022) is among the first demonstrations. This platform could be extended to respiratory viruses, flaviviruses, and beyond.
Plant-Derived tRFs: Cross-Kingdom RNA Therapeutics
The tRF-T11 finding from Increasepharm HK (2022) establishes that exogenous plant tRNA-derived fragments can enter mammalian cells, load into the RISC/AGO2 complex, and suppress oncogenes. This opens a cross-kingdom small RNA therapeutic paradigm distinct from synthetic siRNA or ASO approaches.
tRF Biomarker-to-Therapeutic Pipeline
Multiple records document tsRNA dysregulation across a wide spectrum of cancers, metabolic diseases, and viral infections. The convergence of tRF expression atlases (DBtRend 2021, MINTbase v2.0 2017) with functional characterisation suggests an imminent transition from biomarker to direct therapeutic target — mirroring the miRNA therapeutic trajectory.
IP Strategy and R&D Priorities for tRNA Therapeutics
In this dataset, tRFs have a robust scientific literature base — covering biogenesis, function, and disease association — but minimal dedicated patent coverage. R&D teams and IP strategists should prioritise freedom-to-operate analysis and early filing on tRF sequences with demonstrated oncogene-silencing activity, particularly plant-derived cross-kingdom tRFs which represent a structurally novel chemical entity class.
The dual-use nature of ACE-tRNAs — PTC suppression for rare disease versus replication control for vaccines — means that regulatory classification and CMC frameworks will be product-specific. Early engagement with FDA and EMA on the biologics classification of engineered tRNA therapeutics is advisable.
The availability of a complete drug discovery toolkit for PfKRS (University of Dundee, 2022) — including crystal structures, resistance mutants, and chemical probes — lowers the barrier to entry for pharma partnerships targeting antimalarial aaRS inhibition. The macromolecular interaction approach targeting the tRNA:aaRS interface is particularly attractive for overcoming drug resistance in protozoan parasites, as validated by WHO-recognised neglected tropical disease programs.
Unlike siRNA and mRNA, which benefit from LNP delivery platforms validated by Patisiran and COVID-19 vaccines, engineered tRNA molecules present unique delivery challenges (size ~75 nt, heavily structured, extensively modified). Leveraging and adapting existing LNP or conjugate delivery technologies to tRNA cargo is a critical near-term R&D priority. For enterprise-grade IP management of tRNA delivery platform patents, PatSnap's trust center provides secure portfolio analysis infrastructure.
tRNA Therapeutic Technology — Key Questions Answered
tRNA therapeutic technology spans four mechanistically distinct sub-domains: Anticodon-Engineered tRNAs (ACE-tRNAs) for premature termination codon suppression and vaccine platforms; tRNA-Derived Small RNAs (tRFs and tiRNAs) as microRNA-like regulatory and anticancer agents; Aminoacyl-tRNA Synthetase (aaRS) inhibition for anti-infective and oncology applications; and tRNA modifications as therapeutic targets regulating aminoacylation, immune evasion, and translational fidelity.
ACE-tRNAs are synthetic tRNA molecules in which the anticodon sequence is redesigned to recognize and decode PTCs (UAA, UAG, UGA). This approach enables restoration of full-length protein from mRNA harboring disease-causing nonsense mutations, or — in a novel vaccine application — controlled replication of PTC-containing viruses to generate immunogenic but replication-defective vaccine strains. ACE-tRNAs demonstrated higher PTC readthrough efficacy than GCE technology and site-specific preference, as reported by Harbin Veterinary Research Institute (2022).
tRF-T11, a 5'-derived tRF mimic from plant tRNAHis, demonstrated comparable anticancer potency to taxol at 16-fold lower dosage via AGO2-mediated TRPA1 silencing in ovarian cancer cells, reported by Increasepharm (HK) Limited (2022). tRF dysregulation is documented across breast, lung, prostate, ovarian, and colorectal cancers by Central South University (2020) and Ningbo University (2021).
The lysyl-tRNA synthetase of Plasmodium falciparum (PfKRS) is the most advanced target, with a complete drug discovery toolkit described by the University of Dundee (2022) including resistant mutant generation, hybrid crystal structures, chemical probes, and TPP tools. Tryptophanyl-tRNA synthetase (WRS) is proposed as a multi-indication pharmacological target across sepsis, cancer, and autoimmune/neurological diseases by KRIBB and Korea University of Science and Technology (2021). Parasite-specific tRNA:aaRS interfaces in Leishmania and Trypanosoma are also identified as macromolecular interaction targets.
Five directional signals stand out from the most recent records (2022–2025): ACE-tRNA as a programmable vaccine and gene therapy platform; plant-derived tRFs as a new class of cross-kingdom RNA therapeutics; tRF-based biomarker-to-therapeutic pipeline transitioning from expression atlases to direct therapeutic targets; tRNA modification enzymes (TrmA, TruB) as precision targets for selective translation modulation; and high-potency synthetic mRNA with plant 5' UTR elements (Arcturus Therapeutics, EP 2025) representing convergence between tRNA-aminoacylation and mRNA engineering.
Unlike siRNA and mRNA, which benefit from LNP delivery platforms validated by Patisiran and COVID-19 vaccines, engineered tRNA molecules present unique delivery challenges (size ~75 nt, heavily structured, extensively modified). Leveraging and adapting existing LNP or conjugate delivery technologies to tRNA cargo is a critical near-term R&D priority for any tRNA therapeutic program.
Still have questions? Let PatSnap Eureka answer them with live patent and literature intelligence.
Ask PatSnap Eureka About tRNA TherapeuticsAccelerate Your tRNA Therapeutic R&D with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map white space, track competitors, and prioritise IP strategy across RNA therapeutics.
References
- A novel viral vaccine platform based on engineered transfer RNA — Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 2022, CN
- Archaeal pyrrolysyl tRNA synthetase for orthogonal use — European Molecular Biology Laboratory, 2022, KR
- Function and Therapeutic Implications of tRNA Derived Small RNAs — University of Alabama, 2022, US
- A tRNA-derived fragment from Chinese yew suppresses ovarian cancer growth via targeting TRPA1 — Increasepharm (HK) Limited, 2022, HK
- tRNA-derived fragments: Mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections — Ningbo University, 2021, CN
- Transfer RNA-derived small RNAs: potential applications as novel biomarkers for disease diagnosis and prognosis — Central South University, 2020, CN
- Toolkit of Approaches To Support Target-Focused Drug Discovery for Plasmodium falciparum Lysyl tRNA Synthetase — University of Dundee, 2022, UK
- Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target — KRIBB / Korea University of Science and Technology, 2021, KR
- Targeting tRNA-Synthetase Interactions towards Novel Therapeutic Discovery Against Eukaryotic Pathogens — Oak Ridge National Lab, 2019, US
- Targeting tRNA-synthetase interactions towards novel therapeutic discovery against eukaryotic pathogens — Simon Fraser University, 2020, CA
- Modifications in the T arm of tRNA globally determine tRNA maturation, function and cellular fitness — University of Chicago, 2023, US
- Mammalian nuclear TRUB1, mitochondrial TRUB2, and cytoplasmic PUS10 produce conserved pseudouridine 55 in different sets of tRNA — Southern Illinois University, 2020, US
- Native Tertiary Structure and Nucleoside Modifications Suppress tRNA's Intrinsic Ability to Activate the Innate Immune Sensor PKR — Pennsylvania State University, 2013, US
- ELAC1 Repairs tRNAs Cleaved during Ribosome-Associated Quality Control — Harvard Medical School, 2020, US
- ELAC2, an Enzyme for tRNA Maturation, Plays a Role in the Cleavage of a Mature tRNA to Produce a tRNA-Derived RNA Fragment During Respiratory Syncytial Virus Infection — University of Texas Medical Branch, 2021, US
- Human Retrovirus Codon Usage from tRNA Point of View: Therapeutic Insights — University of KwaZulu-Natal, 2013, ZA
- Anticodon-like binding of the HIV-1 tRNA-like element to human lysyl-tRNA synthetase — University of Cincinnati, 2016, US
- MINTbase v2.0: a comprehensive database for tRNA-derived fragments — Thomas Jefferson University, 2017, US
- DBtRend: A Web-Server of tRNA Expression Profiles from Small RNA Sequencing Data in Humans — Catholic University of Korea, 2021, KR
- Therapeutic RNA for treating cancer — BioNTech SE, 2023, IL
- World Health Organization — Neglected Tropical Diseases Program
- U.S. Food and Drug Administration — Biologics Regulatory Framework
- European Medicines Agency — Advanced Therapy Medicinal Products
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.